The Use of Systemically Absorbed Drugs to Explore An In Vitro Bioequivalence Approach For Comparing Non-Systemically Absorbed Active Pharmaceutical Ingredients in Drug Products For Use in Dogs

被引：1

作者：

Martinez, Marilyn N. ^{[1
]}

Fahmy, Raafat ^{[1
]}

Li, Linge ^{[3
]}

Herath, Kithsiri ^{[2
]}

Hollenbeck, R. Gary ^{[2
]}

Ibrahim, Ahmed ^{[2
]}

Hoag, Stephen W. ^{[2
]}

Longstaff, David ^{[1
]}

Gao, Shasha ^{[1
]}

Myers, Michael J. ^{[3
]}

机构：

[1] US FDA, Ctr Vet Med, Off New Anim Drugs, Rockville, MD 20855 USA

[2] Univ Maryland Baltimore, Sch Pharm, Baltimore, MD 21201 USA

[3] US FDA, Ctr Vet Med, Off Appl Sci, Laurel, MD 20708 USA

来源：

PHARMACEUTICAL RESEARCH | 2024年 / 41卷 / 09期

关键词：

Bioequivalence Evaluation of Non-systemically Absorbed Drugs; In Vivo/in Vitro Relationships; Ivermectin; Praziquantel; PARTICLE-SIZE; DISSOLUTION; PRAZIQUANTEL; IVERMECTIN; PHARMACOKINETICS; BIOAVAILABILITY;

D O I：

10.1007/s11095-024-03766-3

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

PurposeCurrently, for veterinary oral formulations containing one or more active pharmaceutical ingredient (API) that are not systemically absorbed and act locally within the gastrointestinal (GI) tract, the use of terminal clinical endpoint bioequivalence (BE) studies is the only option for evaluating product BE. This investigation explored the use of a totality of evidence approach as an alternative to these terminal studies.MethodsThree formulations of tablets containing ivermectin plus praziquantel were manufactured to exhibit distinctly different in vitro release characteristics. Because these APIs are highly permeable, plasma drug concentrations served as a biomarker of in vivo dissolution. Tablets were administered to 27 healthy Beagle dogs (3-way crossover) and the rate and extent of exposure of each API for each formulation was compared in a pairwise manner. These results were compared to product relative in vitro dissolution profiles in 3 media. In vivo and in vitro BE predictions were compared.ResultsIn vivo/in vitro inconsistencies in product relative performance were observed with both compounds when considering product performance across the 3 dissolution media. Formulation comparisons flagged major differences that could explain this outcome.ConclusionsThe finding of an inconsistent in vivo/in vitro relationship confirmed that in vitro dissolution alone cannot assure product BE for veterinary locally acting GI products. However, when combined with a comparison of product composition and manufacturing method, this totality of evidence approach can successfully alert scientists to potential therapeutic inequivalence, thereby supporting FDA's efforts to Replace, Reduce, and/or Refine terminal animal studies.

引用

页码：1797 / 1809

页数：13